Vaccine therapies for patients with glioblastoma

Eli T. Sayegh, Taemin Oh, Shayan Fakurnejad, Orin Bloch, Andrew T. Parsa*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Glioblastoma (GBM) is a high-grade glial tumor with an extremely aggressive clinical course and a median overall survival of only 14.6 months following maximum surgical resection and adjuvant chemoradiotherapy. A central feature of this disease is local and systemic immunosuppression, and defects in patient immune systems are closely associated with tumor progression. Immunotherapy has emerged as an important adjuvant in the therapeutic armamentarium of clinicians caring for patients with GBM. The fundamental aim of immunotherapy is to augment the host antitumor immune response. Active immunotherapy utilizes vaccines to stimulate adaptive immunity against tumor-associated antigens. A vast array of vaccine strategies have advanced from preclinical study to active clinical trials in patients with recurrent or newly diagnosed GBM, including those that employ peptides, heat shock proteins, autologous tumor cells, and dendritic cells. In this review, the rationale for glioma immunotherapy is outlined, and the prevailing forms of vaccine therapy are described.

Original languageEnglish (US)
Pages (from-to)531-546
Number of pages16
JournalJournal of Neuro-Oncology
Issue number3
StatePublished - Sep 20 2014


  • Glioblastoma
  • Glioma
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Vaccine therapies for patients with glioblastoma'. Together they form a unique fingerprint.

Cite this